Uncategorized
LSX Lisbon 2026: Highlights

Lu Rahman shares some of the stand-put momenta at this year’s LSX World Congress in Lisbon.
LSX World Congress Europe has always been a favourite of the DDW team. Bringing together networking, investment, pharma, start-ups and venture capital, the event offers insight into the workings of wider life science funding and investment, as well market opportunities and challenges. This year’s event took place on 25-26 March at the Lisbon Congress Centre – a first as previous events have been held in London. It was integrated with Informa’s Spring Innovation Week, underpinning this area’s relevance to the life science sector. Figures from the two events state that over 5,000 delegates from around 50 countries made the trip to Lisbon.
There were several standout talks. Cody Powers, Partner, ZS Associates, brought attendees to the State of Biotech Markets: A Forward-looking View talk. This synopsis of the markets, the impact of global policy and discussion of the China biotech market, set the tone for much of the event. Powers noted the financial downturn of the previous year and that while Q4 had indeed shown a rebound, it wasn’t enough to cover the deficit. Powers also acknowledged funding is more challenging and has been stuck for a while.
The panel session Investment, Innovation and Influence: Reimagining Europe’s Role in Global Life Sciences, highlighted some key areas of interest such as where in the world does your investment story fit and what are investors buying. The fact that investors want a clear value proposition and story was discussed as was the importance of building a relationship with investors even if they don’t invest immediately.
A stand-out discussion came via Debra Yu, Partner and COO, Panacea Capital, and Sue Yao, Co-Head, Business Development, KLUS PHARMA | KEUM-BIOTECH. They discussed China – as an innovator, its government enabled bioparks. Permissive regulatory change, the growth of Newcos and what these mean for investment, were also covered in the talk: China Investment & Deal Opportunities: Capital, Partnerships and Licensing in the World’s Second-Largest Economy.
A key element of this LSX event was the discussion and focus on cross-sector convergence. Covering the spectrum of life science markets – biotech, pharma, medtech and healthtech – the event has the ability to cover broader issues relating to the overall healthcare sector. One interesting element of the event was examining the role of biotech, data science and diagnostics integrate into the next generation of healthcare delivery.
Discussions were also had on how biotech VCs are actually making decisions in today’s market. The market has meaningfully improved since late 2024 but geopolitics is still very much at play. The current funding environment is showing green shoots and more capital is being allocated within the growth-type stage.
From DDW Volume 27 – Issue 3, Summer 2026 – Read the digital issue here
The post LSX Lisbon 2026: Highlights appeared first on Drug Discovery World (DDW).
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read